Almac at TIDES Europe 2026
Nov 3–5, 2026 Amsterdam, Netherlands ~900 attendees Website
Almac takes part in 2 sessions at TIDES Europe 2026 in Amsterdam, and exhibits at Booth 227. Its sessions cover new manufacturing approaches for peptides and siRNA, including enzyme development for oligonucleotide therapeutics. Specific topics are siRELIS, a convergent enzymatic ligation strategy for siRNA shared with Alnylam Pharmaceuticals, and high-throughput cGMP peptide manufacturing for individualised cancer vaccines.
| Organization | TIDES Europe 2026 Attendance |
|---|---|
Almac Craigavon, United Kingdom | |
Drug development services for small molecules and peptides, including analytical testing, API supply, radiolabelling, formulation and solid-state services. | Booth Exhibiting at Booth 227 Wed, Nov 49:35am–4:15pmThu, Nov 59:35am–4:00pm Talk Tue Nov 3 11:00–11:30 Individualised Cancer Vaccines: Developing a High-throughput cGMP Peptide Manufacturing Philosophy How to make twenty different peptides to clinical quality in twenty days for one patient's personalised cancer vaccine, then do it again. Talk Thu Nov 5 10:45–11:25 Part 1: siRELIS: A Convergent Enzymatic Ligation Strategy for siRNA Manufacturing; Part 2: Enzyme Development for Oligonucleotide Therapeutics Manufacturing Using engineered joining enzymes to assemble siRNA from short building blocks, and what scaling that approach taught two companies. |
Instantly find 20 buyers from Almac
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by Informa Connect or TIDES Europe. Submit a correction